U.S. Markets closed

Why ADMA Biologics Stock Triumphed on Thursday

·2 min read

ADMA Biologics (NASDAQ: ADMA), typically one of the more under-the-radar coronavirus stocks, was very much on the radar of many investors on Thursday. ADMA attracted a degree of renown in 2020 after its convalescent plasma won Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) to fight COVID. As for the bottom line, ADMA booked a net loss of nearly $14 million ($0.07 per share).